NASDAQ:IDYA

Ideaya Biosciences Stock News

Healthcare > Biotechnology

Buy IDYA

*Your capital is at risk

$28.40

+0.530 (+1.90%)

At Close: Jun 03, 2026

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

06:00am, Monday, 27'th Oct 2025

SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted thera

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

06:30am, Monday, 20'th Oct 2025

83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increas

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

06:00am, Monday, 20'th Oct 2025

Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 months in published meta-analysis of metastatic uveal melanoma in the firs

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06:00am, Friday, 26'th Sep 2025

SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ther

IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day (Transcript)

06:41pm, Monday, 08'th Sep 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA ) 10-Year Anniversary R&D Day Conference Call Company Participants Yujiro Hata - Founder, President, CEO & Director Arun D. Singh - Director of Ophthalmic Oncolog

IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst

04:30pm, Monday, 08'th Sep 2025

I am upgrading IDEAYA Biosciences to a "Strong Buy" due to multiple positive clinical updates and robust pipeline progress. Darovasertib showed strong interim phase 2 data in neoadjuvant uveal melanom

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

08:00am, Monday, 08'th Sep 2025

Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodelvy® (Dose level 2); ORR of 33% (3/9; 3cPR) at 15 mg IDE397 plus 10mg/kg

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

06:00am, Monday, 08'th Sep 2025

Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual gains and reduced long-term risk of blindness for patients in th

IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

12:00pm, Sunday, 07'th Sep 2025

80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansi

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

06:00am, Thursday, 04'th Sep 2025

SOUTH SAN FRANCISCO, Calif. , Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patie

IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 Transcript

10:15pm, Wednesday, 03'rd Sep 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA ) Cantor Global Healthcare Conference 2025 September 3, 2025 9:10 AM EDT Company Participants Yujiro Hata - Founder, President, CEO & Director Joshua Bleharski -

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

06:00am, Wednesday, 03'rd Sep 2025

Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic combination rationale with IDE397, IDEAYA's proprietary MAT2A inhib

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide

06:00am, Tuesday, 02'nd Sep 2025

Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US Darovasertib is a small molecule developed for patients wit

IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

02:00pm, Friday, 29'th Aug 2025

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06:00am, Friday, 29'th Aug 2025

SOUTH SAN FRANCISCO, Calif. , Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted thera

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by